Protecting Ireland’s innovation policy environment is key to developing new medicines for patients, and to attracting fresh investments in pharmaceutical manufacturing and research, according to a report published today [Friday] by EY-DKM, the economic advisory consultants.
Irish patients are among the last in western Europe to have access to vital cancer medicines, placing at risk the Government’s target to put Ireland in the top quartile of European countries for cancer survival within the next decade.
Ireland’s research-based pharmaceutical industry is set to save the Government €15 million on medicines by introducing price reductions today [Sunday] for more than 750 packs of innovative medicines
As Ireland signed up today [Friday] to the BeNeLuxA Initiative on pricing and supply of innovative medicines, the Irish Pharmaceutical Healthcare Association (IPHA) has said the focus of policymakers and industry must remain on fixing a slow and inefficient medicines approvals process for Irish patients
The Irish Pharmaceutical Healthcare Association (IPHA), which represents the research-based pharmaceutical industry in Ireland, has said a continued focus on innovation is key to unlocking the potential of new medicines to improve healthcare outcomes and attract investments in the future.
NEW IPHA RESEARCH SHOWS THAT IRELAND CONTINUES TO LAG EUROPE